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HIGHLIGHTS 
 Interim data from prospective observational study of adjunctive brivaracetam in Europe 
 In patients with drug-resistant focal seizures, the 6-month retention rate was 62.1% 
 At 6 months treatment, 53.6% of patients were 50% responders; 7.5% were seizure-free 
 44.2% of patients had improved and 15.4% had worsened health-related quality of life 
from Baseline 
 In this real-world study, BRV was well tolerated and no new safety signals were 
observed 
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ABSTRACT 
Brivaracetam (BRV) is indicated for adjunctive treatment of focal (partial-onset) seizures with 
or without secondary generalisation in patients 4 years of age and older in the European 
Union (EU). An ongoing 12-month, prospective, non-interventional post-marketing study 
(EP0077; NCT02687711) is collecting real-world information on patients receiving treatment 
with adjunctive BRV in Europe. In this study, BRV is prescribed according to routine clinical 
practice and the EU Summary of Product Characteristics. This second interim analysis 
assessed effectiveness, tolerability and health-related quality of life outcomes for up to 6 
months of treatment. 
At the cut-off date (13 April 2018), 266 patients from five countries had attended Visit 1, 
24.1% (64/266) had completed the study, 37.6% (100/266) were ongoing, and 38.3% 
(102/266) had discontinued. In total, 261 patients had at least one dose of BRV and were 
included in the analyses. Patients had a mean time since epilepsy diagnosis of 23.2 years, a 
mean of eight lifetime AEDs (sum of AEDs discontinued prior to study entry and concomitant 
at study entry), and a median of five focal seizures per 28 days during the 3-month 
retrospective Baseline. 66.3% of patients initiated BRV at a dose within the recommended 
starting range (50–100 mg/day) and 87.1% of patients received BRV modal doses within the 
recommended dose range (50–200 mg/day) during the study. Retention rates were 79.1% 
(N = 239) at 3 months and 62.1% (N = 211) at 6 months. The 50% responder rates for focal 
seizures were 46.8% (N = 139) at 3 months and 53.6% (N = 97) at 6 months. The 
proportions of patients who were seizure-free were 10.7% (21/196) and 7.5% (15/199) at 3 
and 6 months of treatment, respectively. Median percent reductions in focal seizure 
frequency per 28 days from Baseline to 3 and 6 months were 34.6% (N = 139) and 53.3% (N 
= 97), respectively. Overall, 44.2% of patients had an improvement and 15.4% had a 
worsening in Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 total score from 
Baseline to 6 months (N = 52). At least one treatment-emergent adverse event (TEAE) was 
reported in 51.0% (133/261) of patients, and 34.5% (90/261) of patients had drug-related 
TEAEs. The most common drug-related TEAEs (≥5% of patients) were drug ineffective 
(7.7%), seizure (6.5%), and fatigue (6.1%). 
In this 6-month interim analysis, BRV showed effectiveness when used in clinical practice in 
five European countries. BRV was well tolerated, and no new safety signals were observed. 
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Abbreviations 
AED, antiepileptic drug; CGIC, Clinical Global Impression of Change; CI, confidence interval; 
FAS, full analysis set; ILAE, International League Against Epilepsy; HRQoL, health-related 
quality of life; LEV, levetiracetam; MedDRA, Medical Dictionary for Regulatory Activities; 
mFAS, modified full analysis set; PGIC, Patient’s Global Impression of Change; QOLIE-31-
P, Patient Weighted Quality of Life in Epilepsy Inventory-Form 31; SD, standard deviation; 
SGS, secondarily generalised seizures; SmPC, Summary of Product Characteristics; SS, 
safety set; TEAE, treatment-emergent adverse event. 
 
1. Introduction 
Brivaracetam (BRV) is a selective, high-affinity ligand for synaptic vesicle protein 2A (Gillard 
et al., 2011). Efficacy and tolerability of adjunctive BRV in adults with focal (partial-onset) 
seizures was established in three randomised, double-blind, placebo-controlled, fixed-dose 
Phase III trials in patients ≥16 years of age (Biton et al., 2014; Klein et al., 2015; Ryvlin et al., 
2014). In the European Union (EU), BRV is approved for adjunctive treatment of focal 
seizures with or without secondary generalisation in patients 4 years of age and older (UCB 
Pharma, 2018). 
This multinational, observational, post-marketing study is designed to collect information on 
the effectiveness of BRV in patients with focal seizures who are treated in clinical practice. In 
the first interim analysis, which included mostly patients recruited from Germany (100/109), 
BRV displayed a tolerability profile consistent with previous data and a discontinuation rate 
of 36% (data cut-off: 5 October 2016) (Steinhoff et al., 2017b). 
We report data from the second interim analysis, in order to determine the effectiveness, 
tolerability and health-related quality of life (HRQoL) outcomes in patients ≥16 years of age 
with focal seizures after receiving 6-month adjunctive treatment with BRV in real-world 
practice. 
 
2. Methods 
2.1. Study design and patients 
EP0077 (BASE: Brivaracetam And Seizure reduction in Epilepsy; ClinicalTrials.gov: 
NCT02687711) is a 12-month, prospective, non-interventional, post-marketing study. This 
study is collecting real-world information on the effectiveness, tolerability, and HRQoL of 
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BRV in patients (≥16 years of age) with a clinical diagnosis of focal (partial-onset) seizures 
(with or without secondary generalisation) who are treated in clinical practice in Europe. The 
primary outcome of this ongoing study is BRV retention at 12 months of treatment. Study 
recruitment is planned for 530 patients. 
Eligible patients have never been treated with BRV before enrolment in this study, and the 
decision to prescribe BRV is made by the treating physician, independently of participation in 
the study. All visits and assessments are scheduled and conducted per routine clinical 
practice, with visits on the day of first BRV dose, and approximately 3, 6, and 12 months 
thereafter. Per routine clinical practice, all patients entering the study are required to use an 
epilepsy/seizure diary. 
This study was conducted using the International League Against Epilepsy (ILAE) 1981 
classifications (Commission on Classification and Terminology of the International League 
Against Epilepsy, 1981), and all data and analyses were based on these classifications. 
Where relevant, the closest corresponding ILAE 2017 classification (Fisher et al., 2017) is 
also provided. 
Written data consent was obtained from the patient, parent(s), or legal representative before 
study participation. The study protocol was reviewed and approved by an Institutional 
Review Board/Independent Ethics committee, per country-specific regulations. 
 
2.2. Outcomes 
This second interim analysis (data cut off: 13 April 2018) assessed effectiveness, tolerability, 
and HRQoL of BRV for up to 6 months. Effectiveness was assessed by BRV retention, 50% 
response (≥50% reduction from Baseline in focal seizures per 28 days), seizure freedom, 
median percent reduction from Baseline in focal seizure frequency per 28 days, and time to 
first seizure after first dose of BRV. 
Where part of standard clinical practice of the participating site, HRQoL (Patient Weighted 
Quality of Life in Epilepsy Inventory-Form 31 [QOLIE-31-P] Version 2) (Cramer et al., 2003), 
changes in cognitive function (EpiTrack) (Lutz and Helmstaedter, 2005), Clinical Global 
Impression of Change (CGIC), and Patient’s Global Impression of Change (PGIC) were 
assessed. 
Measured tolerability outcomes included incidence of treatment-emergent adverse events 
(TEAEs) and TEAEs considered drug-related by the investigator. TEAEs were defined as 
adverse events occurring on or after the date of first BRV administration. Adverse events 
included clinical adverse events and other safety relevant events such as overdose or off-
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label use. Adverse events were considered drug-related if they were reported as related by 
the investigator or if this assessment was missing. 
Post hoc subgroup analyses were performed for effectiveness outcomes by number of 
lifetime antiepileptic drugs (AEDs) (defined as the sum of AEDs discontinued prior to study 
entry and concomitant AEDs taken at study entry), by historical levetiracetam (LEV) use 
(LEV discontinued prior to study entry), and for patients with secondarily generalised 
seizures (SGS) (focal to bilateral tonic-clonic seizures) during Baseline. 
 
2.3. Statistical analyses 
Because this was an observational study, all variables were summarised using descriptive 
statistics, and there were no inferential analyses. No sample size calculation was planned for 
this interim analysis. Data from patients who prematurely withdrew from the study were 
analysed up to the final visit attended. 
The all patients documented set comprised all patients included in the study with valid data 
consent and for whom at least Visit 1 (Baseline) was documented. The safety set (SS) 
comprised all enrolled patients who received at least one dose of BRV. The full analysis set 
(FAS) comprised all patients in the SS who did not receive BRV before entering the study 
(per the protocol, patients with previous BRV use should not have been enrolled). The 
modified FAS (mFAS) comprised all patients in the FAS who were treated according to the 
approved EU Summary of Product Characteristics (SmPC) (UCB Pharma, 2018), 
representing the on-label use of BRV. 
Patients who remained in the study and on BRV treatment for at least 3 months (>90 days) 
or 6 months (>180 days) after first BRV administration were classed as having 3 or 6 months 
retention, and percentages were based on the number of patients who had the opportunity 
to reach their target day of 90 or 180 days by the cut-off date, respectively. Confidence 
intervals (CIs) were calculated using the 2-sided exact (Clopper-Pearson) method. Seizure 
frequency per 28 days was calculated based on diary data for the previous 3 months, i.e., 
the 3 months before first BRV administration for Baseline seizure frequency and the 3 
months before the 3- and 6-month visits. Percent reduction in focal seizure frequency per 28 
days and 50% response were assessed from Baseline to 3 and 6 months. Seizure freedom 
was assessed at 3 and 6 months, and patients were considered seizure-free if they had not 
discontinued the study before the visit, had no seizures before or on the visit date, and had 
available seizure data at the visit. Patients who discontinued the study were counted as not 
seizure-free and patients with missing seizure data at the visit were excluded from the 
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analysis. The time to first seizure after first dose of BRV was analysed using Kaplan-Meier 
methods. 
Clinically meaningful changes from Baseline in QOLIE-31-P total scores and subscales were 
defined according to Borghs et al. (2012) (improvement, no change, or worsening, based on 
the minimally important change), and assessed at 6 months of treatment. CGIC and PGIC 
data were summarised as proportions of patients with improvement, no change, and 
worsening at 6 months. EpiTrack results were assessed as change in total score from 
Baseline to 6 months. 
 
3. Results 
3.1. Patient disposition and baseline characteristics 
The first patient was enrolled on 16 February 2016. At the cut-off date (13 April 2018), 266 
patients from five countries had attended Visit 1 (Fig. 1). Of these, 180 (67.7%) patients had 
completed 3 months of observation, 127 (47.7%) had completed 6 months, and 64 (24.1%) 
had completed the study. Overall, 102 (38.3%) patients had discontinued (Fig. 1). The most 
common primary reasons for discontinuation were adverse events (40 patients [15.0%]) and 
lack of efficacy (39 patients [14.7%]). A total of 261 patients had at least one dose of BRV 
and were included in the SS; none of them were exposed to BRV before entering the study 
and all were therefore included in the FAS. As these two analysis sets represent the same 
group of patients, SS is used to refer to the SS/FAS population throughout the Results 
section. Overall 149 patients received BRV as recommended per the EU SmPC and were 
included in the mFAS. 112 patients were excluded from the mFAS for the following reasons: 
daily dose <50 mg/day (28 patients), daily dose >200 mg/day (22 patients), brivaracetam not 
administered in equal twice-daily doses (57 patients), brivaracetam monotherapy at Baseline 
(two patients), violation of selection criteria (no focal seizures; two patients), and off-label 
use (one patient). One additional patient was listed as having a modal dose of 300 mg/day 
because of a partial date imputation; however, the patient was confirmed to have received 
doses of ≤200 mg/day by the study team, and was therefore included in the mFAS. 
Patients had a mean time since epilepsy diagnosis of 23.2 years (standard deviation [SD] 
14.1) and a median of five focal seizures per 28 days at Baseline (SS; Table 1). Patients had 
taken a mean of eight lifetime AEDs, and 80.1% of patients were taking two or more 
concomitant AEDs at study entry. The most common reason for initiating BRV was lack of 
efficacy of previous treatment (88.1%). Baseline demographics were similar in patients with 
on-label use of BRV (mFAS; Table 1). Epilepsy etiology was known in approximately half the 
patients (Table S1). 
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A total of 147 of 261 (56.3%) patients had seven or more lifetime AEDs. Patients with seven 
or more lifetime AEDs had a longer time since diagnosis and a higher Baseline seizure 
frequency than those with fewer lifetime AEDs (SS; Table S2). A total of 152 (58.2%) 
patients had previously received and discontinued LEV (Table 1). The most common 
reasons for discontinuation of LEV were insufficient efficacy (50.0%), behavioural side 
effects (31.6%), and other intolerance (11.8%). Patients with historical LEV use had a higher 
Baseline seizure frequency than those without historical LEV use (median 6.00 vs 4.67 focal 
seizures per 28 days) and had taken a higher number of lifetime AEDs (mean 8.8 vs 6.8) 
(Table S3). Eighty-four patients (32.2%) had SGS at Baseline, with a median of 1.84 SGS 
per 28 days (Table S4). 
 
3.2. Exposure and dosing 
The mean duration of exposure to BRV was 183.4 days (SD 140.0; median 142.0) in all 
patients with a median modal dose of 100 mg/day (range 0–400 mg/day) (SS). Overall, 
173/261 patients (66.3%) initiated BRV at a dose within the recommended starting range of 
50–100 mg/day (<50 mg/day: 21 [8.0%]; >100–≤200 mg/day: 46 [17.6%]; >200 mg/day: 4 
[1.5%]; missing: 17 [6.5%]). At 6 months, 101/119 patients (84.9%) took BRV at a dose 
within the approved dose range of 50–200 mg/day (<50 mg/day: 4 [1.5%]; >200 mg/day: 14 
[5.4%]). During the study, 223/256 patients (87.1%) received BRV modal doses within the 
recommended dose range (50–200 mg/day); however, 16 (6.3%) received modal doses of 
<50 mg/day and 17 (6.6%) received modal doses of >200 mg/day. 
In patients with on-label use of BRV (mFAS), the mean duration of exposure to BRV was 
188.3 days (SD 139.7; median 147.0). Patients had a median modal dose of 100 mg/day 
(range 50–300 mg/day). 
 
3.3. Effectiveness: overall population 
The 3- and 6-month retention rates were 189/239 (79.1%) and 131/211 (62.1%), respectively 
(SS; Fig. 2A). The Kaplan-Meier estimated median time to discontinuation of BRV or study 
termination was 389 days. Median percent reductions in focal seizure frequency per 28 days 
from Baseline to 3 and 6 months were 34.6% (N = 139) and 53.3% (N = 97), respectively 
(Fig. 2B). The 50% responder rates for focal seizures were 65/139 (46.8%) at 3 months and 
52/97 (53.6%) at 6 months (Fig. 2C). A total of 21/196 (10.7%) and 15/199 (7.5%) patients 
were seizure-free at 3 and 6 months of treatment, respectively (Fig. 2D). The Kaplan-Meier 
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estimated median time to first seizure was 10 days. Similar effectiveness results were 
observed in the mFAS representing on-label use of BRV (Fig. 2). 
 
3.4. Effectiveness: post hoc analyses by number of lifetime AEDs, by historical LEV use, and 
in SGS 
Effectiveness was generally higher in patients with fewer lifetime AEDs before study entry 
than in those with more lifetime AEDs (SS; Fig. S1). In patients with 0–3, 4–6, and ≥7 
lifetime AEDs, 6-month retention rates were 31/41 (75.6%), 29/46 (63.0%), and 71/124 
(57.3%), median percent reductions in focal seizure frequency per 28 days from Baseline to 
6 months were 90.2% (N = 18), 79.2% (N = 20), and 42.4% (N = 59), 50% responder rates 
were 12/18 (66.7%), 14/20 (70.0%), and 26/59 (44.1%), and seizure freedom rates were 
7/37 (18.9%), 5/43 (11.6%), and 3/119 (2.5%), respectively. 
Retention rates at 6 months were 55/83 (66.3%) in patients without historical LEV use and 
76/128 (59.4%) in patients with historical LEV use (SS; Fig. S2). Seizure responses at 6 
months were also numerically higher in patients without historical LEV use than those with 
historical LEV use (median percent reduction in focal seizure frequency per 28 days from 
Baseline: 75.7% [N = 38] vs 44.9% [N = 59]; 50% responder rate: 24/38 [63.2%] vs 28/59 
[47.5%]; seizure freedom: 9/80 [11.3%] vs 6/119 [5.0%]). 
In patients with SGS at Baseline, the 6-month retention rate was 41/70 (58.6%), median 
percent reduction in SGS frequency per 28 days from Baseline to 6 months was 75.9% (N = 
34), 23/34 (67.6%) patients had a 50% reduction in SGS, and 13/71 (18.3%) patients were 
free from SGS at 6 months of treatment (SS; Fig. S3). 
Similar effectiveness results were observed in patients with on-label use of BRV (mFAS; Fig. 
S1, S2, S3). 
 
3.5. Health-related quality of life 
In this study, 44.2% of patients reported an improvement and 15.4% reported a worsening in 
QOLIE-31-P total score from Baseline to 6 months of treatment (SS; N = 52; Fig. 3). In 
physicians’ responses to the CGIC questionnaires at 6 months of treatment (N = 68), 66.2% 
of patients had an overall improvement and 10.3% had a worsening from Baseline. Similar 
results were seen in patients’ responses to the PGIC at 6 months (N = 60; 56.7% 
improvement, 20.0% worsening). 
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The EpiTrack tool was used to assess changes in cognitive function. The mean EpiTrack 
total score was 31.2 (SD 5.9) at Baseline and 32.4 (SD 6.1) at 6 months (SS; N = 33). No 
major changes were observed in the EpiTrack total score at 6 months, with a median change 
from Baseline of 0.0 (Q1 to Q3 −1.0 to 3.0; N = 33). 
 
3.6. Safety and tolerability 
Overall, 133 (51.0%) patients reported at least one TEAE, and 90 (34.5%) had TEAEs 
considered drug-related by the investigator (SS, Table 2). The most common drug-related 
TEAEs (reported in ≥5% of patients) were drug ineffective (7.7%; reported terms included: 
lack of efficacy, insufficient efficacy, discontinuation due to lack of efficacy, and no better 
seizure control), seizure (6.5%), and fatigue (6.1%). Serious drug-related TEAEs reported by 
at least three patients were seizure (11 [4.2%]) and suicidal ideation (3 [1.1%]). 
Discontinuations of BRV due to drug-related TEAEs were reported by 59 patients (22.6%), 
most commonly (≥5%) drug ineffective (19 patients [7.3%]) and seizure (14 [5.4%]). One 
patient died after 28 days of treatment (unexpected death). This death was not considered 
related to BRV by the investigator. The incidences of drug-related TEAEs were similar in 
patients with on-label use of BRV (mFAS; Table 2). 
 
4. Discussion 
The interim results of this prospective, observational study indicate that adjunctive BRV is 
effective and well tolerated in drug-resistant patients (≥16 years) with focal seizures when 
used in clinical practice across five European countries (United Kingdom, Germany, 
Denmark, Ireland, and Netherlands). 
In this study, 3-month (79.1%) and 6-month retention rates (62.1%) for adjunctive BRV were 
comparable with those observed in several retrospective non-interventional studies of BRV 
(3 months: range 79.4–90.8%; 6 months: range 51.5–80.2%) (Steinhoff et al., 2017a; Steinig 
et al., 2017; Villanueva et al., 2019). Seizure assessments at 3 months showed numerically 
higher 50% responder (46.8% vs 21.9–38.9%) and seizure freedom rates (10.7% vs 0–
5.2%) than observed in three randomised, double-blind, placebo-controlled, pivotal Phase III 
trials of adjunctive BRV (Biton et al., 2014; Klein et al., 2015; Ryvlin et al., 2014). Median 
percent reduction in focal seizure frequency from Baseline were at the upper end of the 
range observed in the pivotal trials (34.6% vs 20.0–37.2%). This might be due to differences 
in dosing. In the pivotal trials, patients were randomised to fixed doses (5/20/50 mg/day, 
100/200 mg/day, 20/50/100 mg/day) (Biton et al., 2014; Klein et al., 2015; Ryvlin et al., 
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2014), whereas in this non-interventional study reflecting real life medical practice, doses 
were determined by the treating physician, and individualised to the needs of a specific 
patient. In this interim analysis, 66.3% of patients initiated BRV at a dose within the 
recommended starting range of 50–100 mg/day (UCB Pharma, 2018) and received modal 
doses of 50–200 mg/day during the study. At 6 months, 53.6% of patients were 50% 
responders and 7.5% were seizure-free, with a median percent reduction in focal seizure 
frequency from Baseline of 53.3%. Similar 3- and 6-month 50% responder (3 months: 41.2–
42.4%; 6 months: 27.8–40.5%) and seizure freedom rates (3 months: 14.9–19.1%; 6 
months: 6.9–17.2%) were reported in other non-interventional studies of BRV (Steinhoff et 
al., 2017a; Steinig et al., 2017; Villanueva et al., 2019). 
As in the pivotal trials (Biton et al., 2014; Klein et al., 2015; Ryvlin et al., 2014) and 
retrospective studies of BRV (Steinhoff et al., 2017a; Steinig et al., 2017; Villanueva et al., 
2019), the Baseline characteristics in this study indicated that the patient population was 
highly drug-resistant. Effectiveness data should be viewed in that context. Enrolled patients 
had a long history of epilepsy, with a mean time since diagnosis of 23.2 years. Patients had 
a median of five focal seizures per 28 days at Baseline, although 80.1% were receiving 
treatment with two or more concomitant AEDs. Overall, 56.3% of patients had seven or more 
lifetime AEDs, and 88.1% initiated BRV because of a lack of efficacy of previous AED 
treatment. 
Post hoc subgroup analyses showed numerically better effectiveness in patients with 0–3 or 
4–6 lifetime AEDs than those with seven or more lifetime AEDs. This is not unexpected as 
patients with a high number of lifetime AEDs are more likely to be drug-resistant (Schiller, 
2009; Schiller and Najjar, 2008). In line with this, patients with seven or more lifetime AEDs 
had a longer time since diagnosis and a higher Baseline seizure frequency than those with 
fewer lifetime AEDs. Consistent with our results, patients with fewer lifetime AEDs were 
more likely to achieve seizure freedom in a retrospective non-interventional study of BRV 
(Villanueva et al., 2019). Furthermore, in a post hoc analysis of a randomized, double-blind 
trial of adjunctive BRV, numerically higher 75% responder rates were seen in patients with 
fewer lifetime AEDs (Klein et al., 2019). 
Effectiveness of BRV in patients with prior LEV use has been demonstrated in retrospective 
studies in clinical practice (Hirsch et al., 2018; Steinig et al., 2017). In the current study, BRV 
was effective regardless of whether patients had historical LEV use; however, responder 
rates and median percent reduction of focal seizures were numerically lower in patients with 
historical LEV use. The subgroup of patients with historical LEV use had a higher Baseline 
seizure frequency and a higher number of lifetime AEDs than those without historical LEV 
use. These factors may have contributed to the observed results. 
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Similar effectiveness results were seen in other studies comparing LEV-naive patients with 
those previously exposed to LEV. In a retrospective non-interventional study of BRV in 
Spain, more LEV-naive patients than those with previous LEV exposure were seizure-free at 
3 (26.0% vs 12.0%), 6 (23.6% vs 11.1%), and 12 months of treatment (17.9% vs 13.4%) 
(Villanueva et al., 2019). In a retrospective study in Germany, higher 6-month retention rates 
were seen in patients without previous LEV use than in the overall population (57% vs 
51.5%) (Steinhoff et al., 2017a). In a post hoc analysis of pooled data from the pivotal trials 
of BRV, 50% responder rates were higher in LEV-naive patients (44.3%) than patients with 
previous LEV exposure (30.0%) (Asadi-Pooya et al., 2017). It should be noted that similar 
results were observed in patients with prior exposure to carbamazepine, lamotrigine, and 
topiramate (Asadi-Pooya et al., 2017). Similar to our study, the subgroups of patients with 
previous exposure to LEV, carbamazepine, lamotrigine, and topiramate had a higher number 
of previously failed AEDs at Baseline, indicating that they were more difficult to treat than 
patients who had never taken these particular AEDs. Nonetheless, BRV was efficacious 
even in patients who had been previously exposed to and failed other AEDs including LEV 
(Asadi-Pooya et al., 2017). A subsequent post hoc analysis of one of the pivotal trials and 
the corresponding open-label extension demonstrated similar long-term retention rates on 
adjunctive BRV and similar reasons for BRV discontinuation in patients with previous LEV, 
carbamazepine, lamotrigine, and topiramate, indicating that previous treatment failure with 
LEV does not preclude the use of BRV (Martin et al., 2018). 
A total of 32.2% of patients had SGS at Baseline. In this subgroup, retention rates were 
similar to those observed in the overall population, while responder rates and seizure 
freedom rates for SGS were numerically higher than those for all focal seizure types in the 
overall population, indicating that BRV may be effective in controlling SGS. These results 
should be interpreted with caution due to the small number of patients with SGS. In a 
retrospective study in Germany, similar responder rates and seizure freedom were seen at 6 
months in all patients with epilepsy (N = 192; all seizure types assessed) and the subgroup 
of patients with generalised tonic-clonic seizures (N = 92; generalised tonic-clonic seizures 
assessed) (Steinig et al., 2017). A post hoc analysis of pooled data from the three pivotal 
trials found that adjunctive BRV was effective in reducing the frequency of SGS in patients 
with drug-resistant seizures (Moseley et al., 2016). 
In the overall population, a numerically higher proportion of patients had an improvement 
than a worsening in HRQoL (QOLIE-31-P) total score and individual domains, CGIC, and 
PGIC, and BRV did not affect cognitive profile as assessed by EpiTrack and the QOLIE-31-P 
subdomain ‘cognitive functioning’. BRV displayed a tolerability profile consistent with its 
known tolerability profile. At the time of this interim analysis, 59/261 (22.6%) patients had 
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discontinued due to drug-related TEAEs. However, it should be noted that the most common 
drug-related TEAEs leading to discontinuation were drug ineffective (19 patients) and 
seizure (14 patients). These events were classified as TEAEs in accordance with the 
European Medicines Agency requirements for safety reporting. 
A potential limitation of the multinational study design is the heterogeneity of data because of 
differences in clinical practice between countries. The interim data reported here should be 
interpreted with caution as they represent a snapshot of the study, with ~50% of planned 
number of patients recruited at the cut-off date. Interpretation of some outcome measures is 
limited by the low patient numbers, as some of the enrolled patients had not yet completed 6 
months of treatment at the cut-off date. In addition, some parameters had not been entered 
into the database at the time of analyses, leading to some missing data, even for patients 
that completed 6 months of treatment. All outcomes in this observational, non-interventional 
study were analysed using descriptive statistics only. Interpretation of the subgroup analyses 
is limited by their post hoc nature and low patient numbers in some of the subgroups. 
 
5. Conclusion 
In this 6-month, second interim analysis of a prospective, observational study, adjunctive 
BRV showed effectiveness in drug-resistant patients when used in clinical practice in five 
European countries. BRV was well tolerated and the reported adverse events were 
consistent with the known tolerability profile reported in pivotal trials. Post hoc analyses 
showed numerically better effectiveness in subgroups of patients with 0–3 or 4–6 lifetime 
AEDs prior to study entry than in those with seven or more lifetime AEDs, who likely 
represent a more drug-resistant patient population. A subgroup analysis of patients with 
SGS at Baseline indicated that BRV may also be effective in controlling SGS. 
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Figure captions 
Fig. 1. Patient disposition (all patients documented set). 
FAS = full analysis set; mFAS = modified full analysis set; SS = safety set. 
a112 patients were excluded from the mFAS for the following reasons: daily dose <50 
mg/day (28 patients), daily dose >200 mg/day (22 patients), brivaracetam not administered 
in equal twice-daily doses (57 patients), brivaracetam monotherapy at Baseline (two 
patients), violation of selection criteria (no focal seizures; two patients), off-label use (one 
patient); one additional patient was listed as having a modal dose of 300 mg/day because of 
a partial date imputation; however, the patient was confirmed to have received doses of 
≤200 mg/day by the study team, and was therefore included in the mFAS. 
 
Fig. 2. Effectiveness outcomes at 3 and 6 months of treatment (SS & mFAS). 
CI = confidence interval; mFAS = modified full analysis set; SS = safety set. 
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(A) Retention rates. Error bars represent 95% CIs. Retention is defined as remaining in the 
study and being on brivaracetam treatment at least 3 months (>90 days) or at least 6 months 
(>180 days) after first brivaracetam administration. Percentages are based on the number of 
patients with data at the respective visit. (B) Median percent reduction in focal seizure 
frequency per 28 days from Baseline based on the number of patients with data at the 
respective visit. (C) 50% responder rates. Percentages are based on the number of patients 
with data at the respective visit. (D) Seizure freedom. Seizure freedom was defined as 
having no seizures recorded in the study on or before the visit date, having not discontinued 
before the visit, and having available seizure data at the visit. 
 
Fig. 3. Clinically meaningful change from Baseline to 6 months of treatment in QOLIE-31-P 
(SS & mFAS). 
mFAS = modified full analysis set; QOLIE-31-P = Patient Weighted Quality of Life in 
Epilepsy Inventory-Form 31; SS = safety set. 
 
Tables 
Table 1 
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Baseline demographics and epilepsy characteristics (SS & mFAS). 
 SS (N = 261) mFAS (N = 149) 
Patient demographics 
Age, mean (SD), years 42.0 (13.2)a 44.3 (13.6) 
Female, n (%) 131 (50.2) 77 (51.7) 
Epilepsy history 
Time since first diagnosis, mean (SD), years 23.2 (14.1)b 23.6 (15.1)c 
Age at first diagnosis, mean (SD), years 18.6 (15.2)b 20.6 (15.9)c 
Baseline seizure frequency per 28 daysd, median (Q1, Q3)   
All seizures 6.00 (3.00, 16.67)e 5.00 (2.33, 12.67)f 
Focal seizures 5.00 (2.00, 16.67)g 4.00 (1.67, 10.00)h 
Antiepileptic drugs 
Historical LEV usei, n (%) 152 (58.2) 84 (56.4) 
Reason for discontinuation of LEVj,k, n (%)   
Insufficient efficacy 76 (50.0) 41 (48.8) 
Behavioural side effects 48 (31.6) 26 (31.0) 
Other intolerance 18 (11.8) 11 (13.1) 
Other 10 (6.6) 6 (7.1) 
Number of lifetime AEDsl, mean (SD) 8.0 (4.9) 7.0 (4.2) 
0–3, n (%) 52 (19.9) 38 (25.5) 
4–6, n (%) 62 (23.8) 37 (24.8) 
≥7, n (%) 147 (56.3) 74 (49.7) 
Concomitant AEDsm at study entry, mean (SD) 2.4 (1.1) 2.2 (1.0) 
0, n (%) 8 (3.1) 4 (2.7)n 
1, n (%) 44 (16.9) 34 (22.8) 
≥2, n (%) 209 (80.1) 111 (74.5) 
Concomitant AEDs used by ≥10% of patients at any time during the study, n (%) 
Lamotrigine 104 (39.8) 62 (41.6) 
Clobazam 71 (27.2) 33 (22.1) 
Levetiracetam 63 (24.1) 40 (26.8) 
Valproate 62 (23.8) 32 (21.5) 
Lacosamide 48 (18.4) 31 (20.8) 
Carbamazepine 45 (17.2) 25 (16.8) 
Zonisamide 42 (16.1) 24 (16.1) 
Reason for initiation of brivaracetamj, n (%) 
Lack of efficacy of previous treatment 230 (88.1) 132 (88.6) 
Behavioural side effects to previous AED 42 (16.1) 24 (16.1) 
Other intolerance to previous AED 33 (12.6) 22 (14.8) 
Administer therapeutic dose without titration 8 (3.1) 5 (3.4) 
Other 10 (3.8) 7 (4.7) 
Missing 1 (0.4) 0 
AED = antiepileptic drug; FAS = full analysis set; LEV = levetiracetam; mFAS = modified full analysis set; Q1 = first quartile; 
Q3 = third quartile; SD = standard deviation; SS = safety set; VNS = vagus nerve stimulation. 
aN = 260; bN = 256; cN = 147; dBased on previous 3 months; eN = 234; fN = 131; gN = 229; hN = 126; iAEDs discontinued 
prior to study entry; jMore than one reason could be given; kPercentage is based on the number of patients with historical 
LEV use; lLifetime AEDs were defined as a sum of the historical AEDs and concomitant AEDs taken at study entry (including 
VNS and LEV counted only once); mVNS was counted as an AED; nThese patients took concomitant AEDs during the study, 
but were counted as having no concomitant AEDs at study entry because of date imputation. 
Table 2 
Summary of TEAEs and drug-related TEAEs (SS & mFAS) 
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Patients, n (%) SS (N = 261) mFAS (N = 149) 
Any TEAEs 133 (51.0) 61 (40.9) 
Serious TEAEs 34 (13.0) 16 (10.7) 
Discontinuations due to TEAEs 72 (27.6) 39 (26.2) 
Deaths 1 (0.4) 0 
Most common TEAEsa (≥5% of patients in the SS)  
Drug ineffectiveb 43 (16.5) 20 (13.4) 
Off-label usec 38 (14.6) 1 (0.7)d 
Seizuree 21 (8.0) 10 (6.7) 
Overdosef 20 (7.7) 0 
Fatigue 17 (6.5) 7 (4.7) 
Drug-related TEAEs 90 (34.5) 47 (31.5) 
Serious drug-related TEAEs 21 (8.0) 12 (8.1) 
Discontinuations due to drug-related TEAEs 59 (22.6) 34 (22.8) 
Most common drug-related TEAEsa (≥1% of patients in the SS)  
Drug ineffectiveb 20 (7.7) 10 (6.7) 
Seizuree 17 (6.5) 10 (6.7) 
Fatigue 16 (6.1) 7 (4.7) 
Dizziness 10 (3.8) 7 (4.7) 
Adverse eventg 9 (3.4) 7 (4.7) 
Headache 7 (2.7) 3 (2.0) 
Irritability 7 (2.7) 2 (1.3) 
Unevaluable eventh 6 (2.3) 5 (3.4) 
Depressed mood 6 (2.3) 3 (2.0) 
Aggression 5 (1.9) 2 (1.3) 
Somnolence 4 (1.5) 2 (1.3) 
Sedation 3 (1.1) 3 (2.0) 
Abnormal behaviour 3 (1.1) 2 (1.3) 
Suicidal ideation 3 (1.1) 2 (1.3) 
Diplopia 3 (1.1) 1 (0.7) 
Disturbance in attention 3 (1.1) 1 (0.7) 
Mood altered 3 (1.1) 1 (0.7) 
Condition aggravatedi 3 (1.1) 0 
TEAEs were listed in accordance with the EMA requirements for safety reporting. 
CGIC = Clinical Global Impression of Change; EMA = European Medicines Agency; MedDRA = Medical Dictionary for 
Regulatory Activities; FAS = full analysis set; mFAS = modified full analysis set; SS = safety set; SmPC = Summary of 
Product Characteristics; TEAE = treatment-emergent adverse event. 
aPreferred Term (MedDRA, Version 21.0); bReported terms included: lack of efficacy, insufficient efficacy, discontinuation 
due to lack of efficacy, and no better seizure control; cReported for situations where brivaracetam is intentionally used for a 
medical purpose not in accordance with the SmPC; dPatient started brivaracetam at a dose of 75 mg twice daily; eReported 
terms included: continuous seizures, discontinuation due to seizure worsening, hospitalisation due to seizures, increased 
seizure frequency, seizure, seizures (multiple episodes), and worsening of seizures; fReported for excessive dosing, 
independently of whether there is an adverse event associated; gReported terms included: adverse event (not otherwise 
specified), much worse / CGIC, and study dropout due to adverse event; hReported terms included: other intolerance, 
remember dreams at night, and increase of attack; iReported terms: CGIC much worse. 
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